Chinese healthcare shares hit their cheapest valuation in history as an AI investment drain starves the sector of capital, sending the Hang Seng Healthcare Index to a record low and punishing blue-chips like WuXi Biologics.
The Hang Seng Healthcare Index plunged to an all-time low as capital rotated to AI stocks. Institutional outflow accelerated after Beijing’s tech push, leaving the index trading at single-digit forward P/E—a record discount to the broader market.
With sentiment overwhelmingly negative and no near-term catalysts, the index could test psychological support levels. However, single-digit P/E multiples historically attract value buyers, limiting downside beyond 5-10%.
A reversal requires either a policy shift—such as new healthcare spending initiatives—or a sharp correction in AI stocks that sends capital back to defensive sectors.
WuXi Biologics, a heavyweight in the index, dropped over 12% in a month as investors fled healthcare for AI. The stock hit a 52-week low amid record-low sector valuation, despite posting steady earnings growth.
While the stock is trading at historically low multiples, the lack of immediate catalysts and persistent sector headwinds suggest it may remain under pressure until the AI rotation fades.
Its global biotech partnerships provide some buffer, but foreign investors are also reducing exposure to China due to geopolitical risks, compounding the domestic rotation.
Mindray Medical, China’s largest medical device maker, fell 8% as the healthcare rout deepened. The stock’s valuation compressed to record levels despite market leadership and consistent earnings, as AI stocks soaked up liquidity.
Mindray is caught in the broader sector rotation; even strong fundamentals can’t shield it from the liquidity drain toward AI. Its valuation has fallen alongside weaker healthcare names.
Yes, long-term demographics favor medical device demand, but in the short term, AI-driven capital flows are overwhelming fundamental valuations.
Baidu, a major Chinese AI player, stands to benefit from the capital rotation out of healthcare. As institutional investors shift funds toward AI stocks, Baidu’s liquidity improves and its valuation multiple could expand on AI optimism.
The capital drain from healthcare is flowing into AI, which is seen as a strategic growth sector. Baidu, with its strong AI portfolio, is a prime beneficiary of this reallocation.
Baidu’s AI cloud and autonomous driving units are growing, but monetization remains uncertain. The stock could rise on sentiment, but fundamentals need to catch up for sustained gains.
China’s healthcare stocks plunged to an all-time valuation low, with the Hang Seng Healthcare Index shedding 3.2% to close below the 2025 trough. The rout accelerated as institutional money fled to AI-related sectors, drawn by Beijing’s tech self-sufficiency push. Blue-chips like WuXi Biologics and Mindray Medical led the losses, with the sector now trading at single-digit forward multiples—a record discount to the broader market.
Investors are rotating capital away from defensive sectors like healthcare and into high-growth AI stocks, driven by Beijing’s strategic emphasis on technological self-sufficiency. This sectoral shift has left healthcare names underowned and undervalued even as earnings hold up.
It refers to the flow of investment money from sectors like healthcare into artificial intelligence companies, which are perceived to have higher growth potential under China’s current industrial policy. This drain has pressured healthcare valuations to record lows.
While valuations are at historic lows, the near-term outlook remains challenged by persistent outflows and a lack of positive catalysts. Bargain hunters may step in, but a sustained recovery likely requires a shift in policy or a pullback in AI hype.